Acrivon Therapeutics Files 8-K on Security Holder Vote

TL;DR

ACRV filed an 8-K, security holders are voting on something important.

AI Summary

On June 20, 2024, Acrivon Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders. The company, incorporated in Delaware, is headquartered in Watertown, Massachusetts, and operates in the pharmaceutical preparations industry.

Why It Matters

This filing indicates that Acrivon Therapeutics is engaging its security holders in a formal voting process, which could pertain to significant corporate actions or governance matters.

Risk Assessment

Risk Level: low — The filing is a routine procedural disclosure regarding a vote by security holders and does not contain information about financial distress or significant operational changes.

Key Numbers

• 001-41551 — SEC File Number (Identifies the company's filing history with the SEC.)
• 82-5125532 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Acrivon Therapeutics, Inc. (company) — Registrant
• June 20, 2024 (date) — Date of earliest event reported
• Watertown, Massachusetts (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ACRV The Nasdaq Stock Mar

Filing Documents

• acrv-20240620.htm (8-K) — 50KB
• 0000950170-24-075760.txt ( ) — 169KB
• acrv-20240620.xsd (EX-101.SCH) — 26KB
• acrv-20240620_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 20, 2024, Acrivon Therapeutics, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, a quorum of 27,422,027 shares of the Company's common stock, or 88.81% of the outstanding shares of common stock entitled to vote as of the record date of April 22, 2024, were present or represented by proxy. Two items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below. Proposal One: Election of Kristina Masson, Ph.D., M.B.A; Sharon Shacham, Ph.D., M.B.A.; and Ivana Magovevi-Liebisch, Ph.D., J.D. as Class II Directors. Kristina Masson, Ph.D., M.B.A; Sharon Shacham, Ph.D., M.B.A.; and Ivana Magovevi-Liebisch, Ph.D., J.D were each elected to serve as a Class II director to hold office until the Company's 2027 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows: For Withheld Broker Non-Votes Kristina Masson, Ph.D., M.B.A. 24,563,469 109,386 2,749,172 Sharon Shacham, Ph.D., M.B.A. 23,268,783 1,466,015 2,687,229 Ivana Magovevi-Liebisch, Ph.D., J.D. 24,498,933 237,318 2,685,776 Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following vote: For Against Abstain Broker Non-Votes 27,405,683 6,036 10,308 -

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acrivon Therapeutics, Inc. Date: June 20, 2024 By: /s/ Peter Blume-Jensen Peter Blume-Jensen, M.D., Ph.D. Chief Executive Officer and President

View Full Filing

View this 8-K filing on SEC EDGAR